

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.

[Fountzilas G](#), [Bobos M](#), [Kalogera-Fountzila A](#), [Xiros N](#), [Murray S](#), [Linardou H](#), [Karayannopoulou G](#), [Koutras AK](#), [Bafaloukos D](#), [Samantas E](#), [Christodoulou C](#), [Economopoulos T](#), [Kalogeras KT](#), [Kosmidis P](#).

Source

Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. fountzil@med.auth.gr

Abstract

The combination of gemcitabine and gefitinib was evaluated in advanced pancreatic cancer. Totally, 53 patients were treated with a 7 week cycle of gemcitabine (1,000 mg/m²) given weekly) followed by six 4 week cycles of gemcitabine given on days 1, 8 and 15. Gefitinib 250 mg was administered daily. Responses were seen in 6, and stabilization of the disease in 12 patients. The main toxicity was myelotoxicity (92%). The 6-month progression-free survival (PFS) was 30%. Median PFS was 4.1 months and median survival 7.3 months with a 1 year survival rate of 27%. The above combination demonstrated promising activity in advanced pancreatic cancer.